46 results on '"Fung, Chunkit"'
Search Results
2. AGS and NIA bench-to bedside conference summary: Cancer and cardiovascular disease.
3. Cardiovascular Risks in Testicular Cancer: Assessment, Prevention, and Treatment
4. Prevalence and risk factors for ototoxicity after cisplatin-based chemotherapy
5. Comprehensive Audiologic Analyses After Cisplatin-Based Chemotherapy
6. The effect of energy from reiki treatments on sleep quality for patients with breast and prostate cancer on hormone therapy.
7. Spontaneous TLS Preceding the Diagnosis of Metastatic Prostate Cancer
8. A phase II trial of enzalutamide (Enz) with 5-alpha reductase inhibitors (5-ARI) as an androgen deprivation therapy (ADT)–sparing approach for older men with castration-sensitive prostate cancer (CSPC).
9. How to Manage Cisplatin-Based Chemotherapy–Related Cardiovascular Disease in Patients With Testicular Cancer
10. Exemestane Treatment in a Male Patient With Concurrent Breast and Prostate Cancers: A Case Report.
11. High‐dose vitamin D to attenuate bone loss in patients with prostate cancer on androgen deprivation therapy: A phase 2 RCT.
12. Ototoxicity After Cisplatin-Based Chemotherapy: Factors Associated With Discrepancies Between Patient-Reported Outcomes and Audiometric Assessments
13. Supplemental Materials from Clinical and Genome-wide Analysis of Cisplatin-induced Tinnitus Implicates Novel Ototoxic Mechanisms
14. Impact of Pain and Adverse Health Outcomes on Long-term U.S. Testicular Cancer Survivors
15. State of Cancer Care in America: Achieving Cancer Health Equity Among Sexual and Gender Minority Communities
16. Adolescent and Young Adult Germ Cell Tumors: Epidemiology, Genomics, Treatment, and Survivorship
17. Cisplatin, environmental metals, and cardiovascular disease: an urgent need to understand underlying mechanisms
18. Impact of pain and adverse health outcomes on long-term US testicular cancer survivors.
19. Adolescent and Young Adult Germ Cell Tumors: Epidemiology, Genomics, Treatment, and Survivorship.
20. Coverage for evidence-based cancer survivorship care services
21. Patient-Reported Functional Impairment Due to Hearing Loss and Tinnitus After Cisplatin-Based Chemotherapy
22. Supplementary Table S2 from Variants in WFS1 and Other Mendelian Deafness Genes Are Associated with Cisplatin-Associated Ototoxicity
23. Supplementary Figure S4 from Variants in WFS1 and Other Mendelian Deafness Genes Are Associated with Cisplatin-Associated Ototoxicity
24. Supplementary data from Clinical and Genome-wide Analysis of Cisplatin-induced Tinnitus Implicates Novel Ototoxic Mechanisms
25. Supplementary Material from Clinical and Genome-Wide Analysis of Serum Platinum Levels after Cisplatin-Based Chemotherapy
26. Supplementary Figures and Tables from Clinical and Genome-Wide Analysis of Cisplatin-Induced Peripheral Neuropathy in Survivors of Adult-Onset Cancer
27. Supplementary Data from Clinical and Genome-Wide Analysis of Multiple Severe Cisplatin-Induced Neurotoxicities in Adult-Onset Cancer Survivors
28. Lack of hydroxyurea‐associated mutagenesis in pediatric sickle cell disease patients
29. Effect of Yoga and Mediational Influence of Fatigue on Walking, Physical Activity, and Quality of Life Among Cancer Survivors
30. Prevalence and Risk Factors for Ototoxicity After Cisplatin-based Chemotherapy
31. Feasibility Of An Evidence-based Exercise Intervention With Electronic Medical Record Integration For Testicular Cancer Survivors
32. Medicare Accountable Care Organizations: Post-acute Care Use and Post-surgical Outcomes in Urologic Cancer Surgery
33. Denials of coverage for evidence-based cancer survivorship care services
34. Cisplatin-induced tinnitus (CIS-TINN) and patient-reported outcomes in adult-onset cancer survivors.
35. Impact of cisplatin-induced hearing loss (CIHL) on patient-reported social and emotional functioning.
36. Building a model to predict the risk of multiple severe neurotoxicities in cancer survivors after cisplatin treatment.
37. Impact of adverse health outcomes (AHOs) on self-reported physical and mental health in U.S. testicular cancer survivors (TCS).
38. A phase 2 study of cabozantinib in combination with atezolizumab as neoadjuvant treatment for muscle-invasive bladder cancer (HCRN GU18-343) ABATE study.
39. Comprehensive association analysis of speech recognition thresholds after cisplatin‐based chemotherapy in survivors of adult‐onset cancer.
40. Increased risk of high-grade prostate cancer among testicular cancer survivors
41. Re: Thyroid hypofunction in aging testicular cancer survivors
42. Testicular Cancer Survivorship: Looking Back to Move Forward
43. Pharmacogenomics of cisplatin‐induced neurotoxicities: Hearing loss, tinnitus, and peripheral sensory neuropathy.
44. The impact of population pharmacogenomics and risk allele frequencies on cisplatin-induced peripheral sensory neuropathy (PSN).
45. Cognitive function in long-term testicular cancer survivors: Impact of modifiable factors.
46. Impact of pain and adverse health outcomes on long-term US testicular cancer survivors.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.